Anna Åleskog

Telomere length as a prognostic parameter in chronic lymphocytic leukemia with special reference to VH gene mutation status

Pawel Grabowski, Magnus Hultdin, Karin Karlsson et al. · Blood · 2005 · 116 citations · Full text

In vitro evaluation of clinical activity and toxicity of anticancer drugs using tumor cells from patients and cells representing normal tissues

Caroline Haglund, Anna Åleskog, Peter Nygren et al. · Cancer Chemotherapy and Pharmacology · 2011 · 38 citations

Normal Tissues, Oncology, Medicine +10

Patients with chronic lymphocytic leukemia with mutated VH genes presenting with Binet stage B or C form a subgroup with a poor outcome.

Gerard Tobin, Ulf Thunberg, Anna Laurell et al. · PubMed · 2005 · 37 citations

The G(-248)A polymorphism in the promoter region of the Bax gene does not correlate with prognostic markers or overall survival in chronic lymphocytic leukemia

Å Skogsberg, Gerard Tobin, Alexander Kröber et al. · Leukemia · 2005 · 36 citations

Hematological Malignancy, Oncology, Promoter Region +10

Significant cytotoxic activity <i>in vitro</i> of the EGFR tyrosine kinase inhibitor gefitinib in acute myeloblastic leukaemia

Elin Lindhagen, Anna Eriksson, Malin Wickström et al. · European Journal Of Haematology · 2008 · 30 citations · Full text